Trials / Terminated
TerminatedNCT02783573
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,722 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanabecestat | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2018-09-28
- Completion
- 2018-09-28
- First posted
- 2016-05-26
- Last updated
- 2019-12-03
- Results posted
- 2019-08-06
Locations
262 sites across 18 countries: United States, Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russia, South Korea, Spain, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT02783573. Inclusion in this directory is not an endorsement.